M Schmalzing1, H-P Tony. 1. Medizinische Klinik und Poliklinik II: Rheumatologie/Klinische Immunologie, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Deutschland, schmalzing_m@ukw.de.
Abstract
BACKGROUND: B cells play a key role in the pathogenesis of various rheumatic autoimmune diseases and have therefore become an important therapeutic target. Rituximab is a chimeric monoclonal anti-CD20 antibody that induces a nearly complete, transient depletion of peripheral CD20-positive B cells. In 2006 rituximab received approval for use in patients with rheumatoid arthritis (RA) and in 2013 for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). OBJECTIVES: In this review various clinically relevant aspects of B cell therapy in RA patients are discussed, including its role in the therapeutic algorithm as well as data on long-term efficacy and safety.
BACKGROUND: B cells play a key role in the pathogenesis of various rheumatic autoimmune diseases and have therefore become an important therapeutic target. Rituximab is a chimeric monoclonal anti-CD20 antibody that induces a nearly complete, transient depletion of peripheral CD20-positive B cells. In 2006 rituximab received approval for use in patients with rheumatoid arthritis (RA) and in 2013 for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). OBJECTIVES: In this review various clinically relevant aspects of B cell therapy in RApatients are discussed, including its role in the therapeutic algorithm as well as data on long-term efficacy and safety.
Authors: Pablo Engel; José A Gómez-Puerta; Manuel Ramos-Casals; Francisco Lozano; Xavier Bosch Journal: Pharmacol Rev Date: 2011-01-18 Impact factor: 25.468
Authors: Joan T Merrill; C Michael Neuwelt; Daniel J Wallace; Joseph C Shanahan; Kevin M Latinis; James C Oates; Tammy O Utset; Caroline Gordon; David A Isenberg; Hsin-Ju Hsieh; David Zhang; Paul G Brunetta Journal: Arthritis Rheum Date: 2010-01
Authors: Paul Emery; Philip J Mease; Andrea Rubbert-Roth; Jeffrey R Curtis; Ulf Müller-Ladner; Norman B Gaylis; Sarah Williams; Mark Reynard; Helen Tyrrell Journal: Rheumatology (Oxford) Date: 2011-09-16 Impact factor: 7.580
Authors: Joerg Wendler; Gerd R Burmester; Helmut Sörensen; Andreas Krause; Constanze Richter; Hans-Peter Tony; Andrea Rubbert-Roth; Peter Bartz-Bazzanella; Siegfried Wassenberg; Iris Haug-Rost; Thomas Dörner Journal: Arthritis Res Ther Date: 2014-03-26 Impact factor: 5.156
Authors: P Emery; J E Gottenberg; A Rubbert-Roth; P Sarzi-Puttini; D Choquette; V M Martínez Taboada; L Barile-Fabris; R J Moots; A Ostor; A Andrianakos; E Gemmen; C Mpofu; C Chung; L Hinsch Gylvin; A Finckh Journal: Ann Rheum Dis Date: 2014-01-17 Impact factor: 19.103
Authors: Charles H Pritchard; Maria W Greenwald; Joel M Kremer; Norman B Gaylis; William Rigby; Steve Zlotnick; Carol Chung; Birgit Jaber; William Reiss Journal: BMC Musculoskelet Disord Date: 2014-05-24 Impact factor: 2.362